Nimacimab (RYI-018) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases[1][2].
[1]. Priyadarshini Loganathan, et al. Current and future treatment management strategies for gastroparesis. Expert Review of Endocrinology & Metabolism 16:2, pages 25-35.
[2]. Dao M, et al. Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox. Front Endocrinol (Lausanne). 2021 Jul 7;12:720734.
















